Navigation Links
ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease
Date:12/7/2009

ions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implementation of ChemoCentryx's business model, strategic plans for its business, product candidates and technology, (vi) ChemoCentryx's ability to maintain and establish collaborations or obtain additional government grant funding, (vii) ChemoCentryx's estimates of its expenses, future revenues, capital requirements and its needs for additional financing, (viii) the timing or likelihood of regulatory filings and approvals, (ix) the availability of corporate partners, (x) the scope of protection ChemoCentryx is able to establish and maintain for intellectual property rights covering its product candidates and technology, (xi) the impact of competitive products and technological changes, (xii) the availability of capital and the cost of capital, (xiii) ChemoCentryx's financial performance, (xiv) developments relating to ChemoCentryx's competitors and other vagaries in the biotechnology industry and (xv) other risks.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and ChemoCentryx undertakes no obligation to revise or update this press release to reflect event
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
2. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
7. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
8. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
9. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
10. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
11. Pharmasset Reports Fiscal Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ergonomically ... with Hitachi Koki of Japan ... North America . NuAire will utilize its network of ... Canada to offer assistance in application use, ...
(Date:1/14/2014)... Oligomerix, Inc. , a privately held company pioneering the ... and related neurodegenerative disorders, announced today the relocation of ... as of January 15, 2014 and expanded lease ... College. Oligomerix, which is focused on the ...
(Date:1/14/2014)...   Evidera , a leading provider of evidence-based solutions ... Drug Evaluation and Research (CDER), U.S. Food and Drug ... for a patient-reported outcome (PRO) measure in drug development: ... [EXACT] for Measurement of Symptoms of Acute Bacterial Exacerbation ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
(Date:4/17/2014)... BostonResearchers from Boston University School of Medicine (BUSM) ... alcohol consumption in an experimental model. The findings, ... and Alcohol Abuse , may lead to more ... alcohol is one of the leading causes of ... significant negative economic impact by limiting the productivity ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
(Date:4/17/2014)... alleviates muscle soreness after exercise, according to a ... at Chicago. , The study, reported online in ... Physical Medicine and Rehabilitation , also showed that ... not exercised, suggesting that massage has benefits for ... , Improved circulation and relief of muscle soreness ...
(Date:4/17/2014)... 17, 2014 Giving patients adrenaline after they suffer a ... their prospects of surviving long-term, according to new research ... of patients who have a cardiac arrest get adrenaline, ... arrest for decades," said Dr. Steve Lin, an emergency ... despite advances in medical treatment, long-term survival rates of ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:New MRSA superbug emerges in Brazil 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... Acknowledges Decades of Service WILMINGTON, Del., May 1 ... the non-profit segment running smoothly in tough economic ... is making sure their volunteers get the recognition ... to premiere this spring, with a whimsical, permanent ...
... honors journalists for orthopaedic-related coverageROSEMONT, Ill., May 1 ... (AAOS) has announced the winners of its 2009 ... year and honors media efforts that further public understanding ... the care of bones, joints, muscles and tendons. ...
... this Sunday, May 3, 2009 for one of the country,s ... Millions were moved by his voice, now thousands more will ... Cook takes to a different kind of stage, leading ... Cassidy & Pinkard Colliers National Race for Hope, this Sunday, ...
... Offering of Avalign Technologies, Inc.LAKE FOREST, Ill., ... an operating-oriented private equity firm focused exclusively ... its portfolio company, Avalign Technologies, Inc. ... implants, and delivery systems to the OEM ...
... As H1N1 influenza A (swine flu) spreads, keeping hands ... prevent infection and illness. "Frequent handwashing is probably ... do to protect yourself and your family," according to ... Microbiology."Influenza A viruses, of which swine flu is one, ...
... Director,s Award presented at 2009 Dish benefitSAINT PAUL, ... Upper Midwest,s largest hunger-relief organization, has honored David ... Foundation and founder of the nation,s first food ... Award. The award recognizes outstanding individual contributions to ...
Cached Medicine News:Health News:Artist Contributes to Volunteer Recognition 2Health News:American Academy of Orthopaedic Surgeons Announces Media Orthopaedic Reporting Excellence (MORE) Award Winners 2Health News:American Academy of Orthopaedic Surgeons Announces Media Orthopaedic Reporting Excellence (MORE) Award Winners 3Health News:American Idol David Cook Headlines National Race for Hope 2Health News:RoundTable Healthcare Partners Completes Portfolio Company Add-On Acquisition 2Health News:RoundTable Healthcare Partners Completes Portfolio Company Add-On Acquisition 3Health News:American Society for Microbiology Emphasizes Hand Hygiene as Flu Protective Measure 2Health News:Second Harvest Heartland Honors Hunger Hero David Nasby 2Health News:Second Harvest Heartland Honors Hunger Hero David Nasby 3
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
20 gauge x 8 mm with 15 cm high pressure extension tube preattached to a 10C ring control syringe. 3 per box....
Sharp tip with cutting edge bent to 50 degrees fits 19 gauge or 20 gauge instrument port, 20 gauge instrument port, 20 gauge x 25 mm tapering to 25 gauge x 4.76 mm. 10 per box....
Angled, 20 gauge x 25 mm cannula with 30 gauge x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub, angled 45 degrees 2.5 mm from tip. 10 per box....
Medicine Products: